The U.S. Food and Drug Administration has approved Shionogi's Xocova (ensitrelvir), an oral antiviral, for postexposure ...

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...

The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention landscape. Amid the approval, Noah Greenspan, DPT, PT, owner and founder of ...

In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).

REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. The Food and Drug Administration (FDA) has ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A single subcutaneous dose of Regeneron’s antibody ...

Shionogi (TSE:4507) has just received U.S. FDA approval for XOCOVA (ensitrelvir) as an oral post exposure prophylaxis for COVID-19 in adults and adolescents, marking the first approved drug of its ...